Loading stock data…
SXTP
$1.66+0.01 (+0.61%)
After Hours$1.66+0.00 (+0.00%)· Last close May 6
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
60 Degrees Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.67. The stock is currently near its 52-week low of $1.29, remaining 57.5% below its 200-day moving average. Technical signals show neutral RSI of 46 and bullish MACD crossover, explaining why SXTP maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.66
Potential Upside
5%
Whystock Fair Value$1.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-212.67%
Volume
Today's trading volume
44,197
Recent News
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the affordability and accessibility of ARAKODA (tafenoquine), the only FDA-approved, once-weekly prescription medication for malaria prevention in the US. The collaboration allows eligible patients to […]
Is GoodRx (GDRX) Using ARAKODA Discounts To Quietly Redefine Its Preventive Care Strategy?
In February 2026, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to offer eligible U.S. consumers savings of up to 30% on ARAKODA, the only FDA-approved, once-weekly prescription malaria prevention, across more than 70,000 pharmacies and home delivery where available. This collaboration broadens GoodRx’s presence in travel-related preventive care, linking its discount platform to a specialized medication for malaria risk management. Next, we’ll examine how expanding into...
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index up 0.2% and t
Top Midday Gainers
60 Degrees Pharmaceuticals (SXTP) reported Thursday a partnership with Runway Health to boost access